多肽需求持续高增,药明康德TIDES业务单季度收入再创新高至27.9亿元

时代财经
Jul 28, 2025

本文来源:时代财经7月28日,药明康德(603259.SH;02359.HK)披露了2025年上半年业绩报告。财报显示,今年上半年,持续受市场关注的TIDES业务(寡核苷酸和多肽)保持高速增长,实现收入50.3亿元,同比增长141.6%。从单季度来看,该业务在今年第二季度实现收入27.9亿元,再创单季度新高。TIDES业务收入不断创新高的同时,药明康德持续推进泰兴多肽产能建设,预计至2025年底,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10